Safety aspects of probiotic bacterial strains Lactobacillus rhamnosus HN001 and Bifidobacterium animalis subsp. lactis HN019 in human infants aged 0–2 years

Dekker, James; Wickens, Kristin; Black, Peter; Stanley, Thorsten; Mitchell, Edwin A.; Fitzharris, Penny; Tannock, Gerald W.; Purdie, Gordon; Crane, Julian

doi:10.1016/j.idairyj.2008.10.004

Cited by 32 publications

(28 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In reports focusing on safety, AE were not attributable to the supplemented organisms in infants administered Lactobacillus rhamnosus HN001 and Bifidobacterium animalis subsp. lactis HN019 (12), combinations of Bifidobacterium longum BL999, Lactobacillus rhamnosus LPR and Lactobacillus paracasei ST11 (13), and Bifidobacterium lactis BB-12 and Lactobacillus reuteri ATCC 55730 (14). Similarly, adverse outcomes have not been associated with infant formula milks containing 1 or more bacterial species with a prebiotic; organisms have included Bifidobacterium longum BL999 (15), Lactobacillus rhamnosus GG and LC705, Bifidobacterium breve Bb99 and Propionibacterium freudenreichii spp.…”

Section: Discussionmentioning

confidence: 99%

Dietary Supplementation with Lactobacilli and Bifidobacteria Is Well Tolerated and Not Associated with Adverse Events during Late Pregnancy and Early Infancy

Allen

Jordan

Storey

et al. 2010

The Journal of Nutrition

100

View full text Add to dashboard Cite

Lactic acid bacteria and bifidobacteria are increasingly being administered to pregnant women and infants with the intention of improving health. Although these organisms have a long record of safe use, it is important to identify any adverse effects in potentially vulnerable populations. In a randomized, double-blinded, placebo-controlled trial, we evaluated the safety of a bacterial dietary supplement for the prevention of atopy in infants. Two strains of lactobacilli (Lactobacillus salivarius CUL61 and Lactobacillus paracasei CUL08) and bifidobacteria (Bifidobacterium animalis subsp. lactis CUL34 and Bifidobacterium bifidum CUL20) with a total of 1 x 10(10) colony-forming units were administered daily to women during the last month of pregnancy and to infants aged 0-6 mo. Adverse events (AE) were classified according to WHO International Statistical Classification of Diseases criteria. Common symptoms were recorded by regular questionnaires. Baseline characteristics of 220 mother-infant dyads in the treatment and 234 in the placebo group were similar. Compliance with the trial interventions, loss to follow-up, symptoms, drug usage, infant growth, method of feeding, visits to the doctor, and mothers' assessment of infant health were similar in the 2 groups. Fifteen (6.8%) mothers and 73 (33.2%) infants in the treatment group and 21 (9.0%) mothers and 75 (32.1%) infants in the placebo group reported AE (P = 0.49 and P = 0.84, respectively). Severe AE occurred in 18 mothers and 63 infants with a similar frequency in each group. None of the AE were attributed to the intervention. Our findings support the safe use of this consortium of organisms during pregnancy and early infancy.

show abstract

Section: Discussionmentioning

confidence: 99%

Dietary Supplementation with Lactobacilli and Bifidobacteria Is Well Tolerated and Not Associated with Adverse Events during Late Pregnancy and Early Infancy

Allen

Jordan

Storey

et al. 2010

The Journal of Nutrition

100

View full text Add to dashboard Cite

show abstract

“…The strain HN019 is nontoxic to mice (10–12) and has been reported to be well tolerated in human infants (13). However, infancy is characterized by microbial plasticity, and limited data on the clinical effectiveness as well as microbiological and metabolic consequences of adding probiotic preparations to infant formula have not been detailed.…”

Section: Introductionmentioning

confidence: 99%

Integrated Role of Bifidobacterium animalis subsp. lactis Supplementation in Gut Microbiota, Immunity, and Metabolism of Infant Rhesus Monkeys

Slupsky

Dekker

et al. 2016

mSystems

Self Cite

View full text Add to dashboard Cite

Probiotics are becoming increasingly popular due to their perceived effects on health, despite a lack of mechanistic information on how they impart these benefits. Infant formula and complementary foods are common targets for supplementation with probiotics. However, different probiotic strains have different properties, and there is a lack of data on long-term health effects on the consumer. Given the increasing interest in supplementation with probiotics and the fact that the gastrointestinal tracts of infants are still immature, we sought to determine whether consumption of infant formula containing the probiotic Bifidobacterium animalis subsp. lactis HN019 for 3 months starting at birth would impact gut microbial colonization, as well as infant immunity and metabolism, when compared with consumption of formula alone.

show abstract

“…Five strains which were identified as L. acidophilus using API 50CHL were identified as L. gasseri using species-specific PCR. Species identification using rep-PCR with primer (GTG) 5 was mostly in accordance with species-specific PCRs with the exception of two strains (RL6, RL20); three strains (RL7, RL27, RL28) were not identified by any one of the amplification methods (Table 1). Therefore, the sequencing of 16S rDNA genes of these 5 strains was performed and the sequences were compared with those in the EMBL database.…”

Section: Strain Identification and Characterisationmentioning

confidence: 74%

“…Due to ecological and commercial interests, substantial efforts have been concentrated in the past years to isolate and identify new strains of lactobacilli [2,4]. Gut and faeces of suckling babies and maternal breast milk seem to be important sources of bacteria for the dairy industry [5]. Lactobacillus strains of human origin are the most suitable for the production of fermented products because some health-promoting benefits are strain specific and can be used optimally in the form in which they were isolated [3,6].…”

Section: Introductionmentioning

confidence: 99%

Selection of potential probiotic Lactobacillus strains of human origin for use in dairy industry

Španová

Dráb²,

Turková

et al. 2015

Eur Food Res Technol

View full text Add to dashboard Cite

Safety aspects of probiotic bacterial strains Lactobacillus rhamnosus HN001 and Bifidobacterium animalis subsp. lactis HN019 in human infants aged 0–2 years

Cited by 32 publications

References 28 publications

Dietary Supplementation with Lactobacilli and Bifidobacteria Is Well Tolerated and Not Associated with Adverse Events during Late Pregnancy and Early Infancy

Dietary Supplementation with Lactobacilli and Bifidobacteria Is Well Tolerated and Not Associated with Adverse Events during Late Pregnancy and Early Infancy

Integrated Role of Bifidobacterium animalis subsp. lactis Supplementation in Gut Microbiota, Immunity, and Metabolism of Infant Rhesus Monkeys

Selection of potential probiotic Lactobacillus strains of human origin for use in dairy industry

Contact Info

Product

Resources

About